

**Fiscal Year 2022 (FY22) Department of Defense Breast Cancer Research Program (BCRP)  
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Research Extension Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT9425-23-BCRP-CREA</a></p>	<p>Investigators at all academic levels (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports research that extends the data collection, follow-up, and analysis of breast cancer clinical research studies.</li> <li>• The intent of this mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to limited or early termination of patient follow-up and sample collection and analysis.</li> <li>• Although not all-inclusive, research proposed under this mechanism may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial.</li> <li>• PIs are required to include two or more breast cancer advocates on their research team.</li> <li>• Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to partner on a single application. <ul style="list-style-type: none"> <li>○ Each PI is expected to bring a distinct contribution to the application.</li> <li>○ The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project.</li> </ul> </li> <li>• Submission of a Letter of Intent is required prior to full application submission.</li> <li>• Clinical trials are not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$5M</b> for direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>4</b> years</li> </ul> <p><b>Partnering PI Option:</b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$6M</b> for direct costs (plus indirect costs).</li> <li>• Maximum period of performance is <b>4</b> years</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> November 29, 2022 5:00 p.m. Eastern time</p> <p><b>Application:</b> December 13, 2022 11:59p.m. Eastern time</p>